Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several positive indicators: a 40% increase in RFP volume from new clients, improved decision-making timelines in biotech, and consistent pricing strategies. The company is focusing on optimizing contracts and achieving operating leverage, with no structural barriers to margin improvement. The CEO's positive surprise regarding workforce morale further supports a positive outlook. However, the lack of 2026 guidance and potential pricing pressures are cautionary notes. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range.
Key Financial Performance
Revenue $701.3 million, 3.9% higher than the prior year quarter, driven by increases in both clinical pharmacology and clinical development businesses with a small benefit from foreign exchange.
Adjusted EBITDA $50.7 million compared to $64.2 million in the prior year period, a decrease driven primarily by lower margin related to project mix, including a higher proportion of pass-through costs, the reintroduction of variable compensation, and a reduction in R&D tax credit.
Backlog Over $7.6 billion, with a book-to-bill ratio of 1.13x, up sequentially from the second quarter, and a trailing 12-month book-to-bill ratio of 1.07x.
Net Loss $15.9 million compared to a net loss of $18.5 million in the prior year period, showing a slight improvement.
Adjusted Net Income $11.7 million compared to $20.7 million in the prior year period, a decrease attributed to lower margins and other financial adjustments.
Operating Cash Flow Positive $87 million for the third quarter, compared to negative operating cash flow of $15.6 million for the 9 months ended September 30, 2025, showing improvement in cash flow management.
Days Sales Outstanding (DSO) 33 days as of September 30, 2025, 13 days lower than June 30, 2025, and 17 days lower than the same period last year, reflecting improved order-to-cash processes.
SG&A Costs Lower year-over-year by 21.6%, primarily due to lower TSA and IT-related costs, with sequential reductions of 7% from Q2 2025 and 20% from Q4 2024 run rate.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New business wins: Secured significant awards with new and repeat clients, including growth in clinical pharmacology and diverse awards in global clinical development. Notable wins include Phase II and III studies in various therapeutic areas such as neuromuscular, ophthalmology, respiratory, and oncology.
Technology and AI adoption: Launched Accelerate Risk Radar for risk-based quality management in clinical trials, Start My Day digital tool for productivity, and ICRA mobile app for CRA workflows. Early users report 5%-10% efficiency gains.
Client demand and win rates: Demand for services grew, with win rates doubling for biotech clients compared to the prior quarter. Strong RFP flow across clinical pharmacology and clinical development.
Strategic partnerships: Secured 2 new strategic partnerships with midsized clients.
Operational improvements: Improved Net Promoter Scores, reduced time to site selection by 33%, accelerated recruitment by 3 months in a respiratory study, and completed enrollment 5 months early in an Alzheimer's study.
Cost optimization: Achieved $95 million in gross savings year-to-date, with $53 million in net savings contributing to EBITDA improvements.
Strategic pillars: Focused on commercial, operational, and financial excellence. Emphasis on expanding client reach, optimizing project management, and driving margin expansion.
Leadership and employee engagement: CEO's first 100 days included extensive client and employee engagement, strengthening partnerships, and fostering a culture of efficiency and innovation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Slight increase in cancellation rate: While the cancellation rate remains within historical range, any increase in cancellations could impact revenue and backlog stability.
Competitive pressures in pricing: Balancing winning new business and achieving attractive margins amid competitive pressures could challenge profitability.
Higher pass-through costs: Increased pass-through costs in clinical pharmacology and development businesses could pressure margins.
Operational challenges in project management: The need for improvement in project management and client relationship management could affect client satisfaction and operational efficiency.
Economic uncertainties and funding variability: While biotech funding improved in Q3, variability in funding and economic conditions could impact demand for services.
Debt and financial leverage: The company is focused on debt paydown and maintaining financial flexibility, but high leverage ratios could pose risks if cash flow targets are not met.
Regulatory and tax-related challenges: Lower R&D tax credits and nondeductible compensation expenses have negatively impacted financials.
Dependence on top clients: Top 10 customers represent 60% of revenues, with the largest customer accounting for nearly 20%, posing concentration risk.
Transformation and cost optimization risks: Ongoing cost optimization initiatives may face execution risks, potentially delaying margin improvements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: For full year 2025, revenue is expected to be in the range of $2.7 billion to $2.75 billion, reflecting an increase in the revenue target.
Adjusted EBITDA Guidance: Adjusted EBITDA for full year 2025 is projected to be in the range of $175 million to $195 million, reflecting operational discipline and confidence in execution.
Cash Flow Outlook: Operating cash flow for full year 2025 is targeted to be marginally negative, with positive operating cash flow expected in the fourth quarter of 2025.
Cost Optimization Initiatives: The company is executing a $150 million gross cost reduction target for 2025, with $90 million net benefit expected this year. SG&A optimization programs are expected to extend into 2026.
Backlog and Book-to-Bill Ratio: Backlog is over $7.6 billion, with a book-to-bill ratio of 1.13x for Q3 2025 and 1.07x for the trailing 12 months. Backlog burn is expected to continue throughout the remainder of 2025.
Operational Efficiency Improvements: Efficiency initiatives include reducing time to site selection by 33%, accelerating recruitment timelines, and leveraging technology and AI for productivity gains. These efforts are expected to improve efficiency, quality, and client delivery.
Technology and AI Deployment: The company plans broader deployment of its AI-powered tools, such as Accelerate Risk Radar and the ICRA mobile app, in 2026 to enhance risk management, productivity, and operational efficiency.
Market Trends and Demand Environment: The demand environment is improving, with growth in clinical trial starts and increased biotech funding in Q3 2025. Biopharma remains resilient, advancing development portfolios.
Capital Allocation Priorities: Priorities include driving organic growth, improving productivity, and debt repayment. The company is focused on maintaining a healthy balance sheet and financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Debt paydown and share repurchase: The company has focused on debt paydown, including a recent tender offer to repurchase up to $75.7 million of the company's outstanding senior secured notes. This action was funded in part by an improved cash position, demonstrating a commitment to maintaining a healthy balance sheet and financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the mix of pre-spin versus post-spin awards and how you see this evolving through 2026?
A:The company is moving away from the vocabulary of pre-spin versus post-spin awards. Contracts signed before Fortrea's spin-off from Labcorp have limited flexibility for rightsizing, but the team is focused on optimizing these contracts. For post-spin contracts, the company is emphasizing out-of-scope work, overburns, and appropriate staffing, which has shown positive results.
Q:Can you provide details on new to Fortrea clients, including any quantitative metrics and strategies to attract them?
A:RFP volume from new to Fortrea clients increased by almost 40% quarter-over-quarter in Q3, and win rates for new biotech clients doubled. The company is focusing on account management, sales strategy, and executive engagement, with leadership actively participating in bid defenses and customer visits.
Q:What trends are you seeing in bookings between large pharma and small biotech, and have you noticed any increased activity due to recent headlines on pharma tariffs?
A:The company sees neutral to favorable trends in both large pharma and small biotech. Biotech decision-making timelines have improved, leading to faster sales cycles. Large pharma customers remain resilient, with prioritized pipelines moving forward despite challenges like tariffs and pricing pressures.
Q:How is the pricing environment in the CRO industry, and have you noticed any changes in competitive intensity?
A:The pricing environment remains competitive but disciplined. Bid margins have stayed consistent, and the company focuses on leading with science, executive engagement, and operational expertise. In the FSP business, there is more aggressive pricing from larger CRO competitors, but Fortrea avoids unattractive pricing.
Q:What is the company's pricing strategy and approach to margin leverage?
A:The company aims to hold pricing where possible but remains competitive for strategic reasons. Leadership is vigilant about pricing and has walked away from deals with unfavorable terms. The focus is on growing direct service fee revenue to achieve operating leverage and improve margins.
Q:Can you provide insights into the biotech operating model and go-to-market strategy?
A:The company adopts a bespoke approach for biotech clients, tailoring strategies based on their specific needs, such as medical expertise, resource gaps, or funding requirements. The focus is on upskilling customer-facing resources to address client challenges effectively.
Q:What are the company's plans to close the margin gap with peers, and are there structural reasons preventing this?
A:There are no structural reasons preventing Fortrea from achieving industry-standard margins. The company plans to focus on rightsizing, consistent backlog growth, and maintaining a nimble CRO approach. Structural headwinds from the spin-off and leadership transition are subsiding.
Q:What is the company's outlook for top-line growth in 2026?
A:The company is not providing 2026 guidance at this time. Leadership needs more time to assess and will provide updates in the future.
Q:Can you provide anecdotes or evidence of improved industry environment and decision-making timelines?
A:In biotech, a client awarded two large Phase III programs after delays due to FDA uncertainties. In large pharma, clients are locking in R&D plans for 2026 as uncertainties around U.S. administration negotiations subside. These examples indicate neutral to positive trends.
Q:How is the Phase I business performing, and what is the progress on bringing more work in-house?
A:Phase I business has seen higher-than-expected growth and healthy utilization rates. Some studies require external sites due to design constraints, leading to higher pass-through costs. The mix of work is the key narrative, with strategic repeat business from large customers.
Q:What is the progress and traction of the dedicated FSP sales team?
A:The FSP sales team has seen an uptick in RFPs, but the sales cycle is longer than FSO. The company is cautious about taking on work with unattractive margins and focuses on healthy-margin opportunities.
Q:Are large pharma clients pushing decision-making timelines for 2026 R&D plans?
A:There is no consistent trend of decision-making being pushed out. Decision-making timelines are normalizing, with variations depending on specific customers.
Q:What have been the biggest surprises for the CEO in his first 100 days at Fortrea?
A:The CEO has been positively surprised by the high morale, commitment, and work ethic of Fortrea's workforce across multiple geographies, despite industry and company-specific challenges.
Q:Review of Unclear Management Responses
A:Management avoided providing specific 2026 guidance, stating it was too early to comment. Additionally, they did not provide detailed numerical breakdowns of direct fee versus pass-through revenue, citing industry norms as a reason for not disclosing such data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI ML
Accelerate
Anshul
CRUs
Chief Executive
Executive Officer
India
Phase II
Phase III
app
area
balance
bill ratio
cash position
client delivery
client relationship
client win
colleague
commitment
culture
demand
disease study
efficiency
employee engagement
expertise
focus client
gain
insight
low
partnership
pharma client
pharmacology
pilot
portfolio
repeat client
study pharma
win rate
workflow
FTRE Transcript
Fortrea Holdings Inc. (FTRE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-2
Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals several positive indicators: a 40% increase in RFP volume from new clients, improved decision-making timelines in biotech, and consistent pricing strategies. The company is focusing on optimizing contracts and achieving operating leverage, with no structural barriers to margin improvement. The CEO's positive surprise regarding workforce morale further supports a positive outlook. However, the lack of 2026 guidance and potential pricing pressures are cautionary notes. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range.
Fortrea Holdings Inc. (FTRE) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call summary reveals strong financial performance with a positive book-to-bill ratio and reaffirmed revenue and EBITDA guidance. Pipeline growth and AI integration suggest strategic advancements. The Q&A section highlighted management's optimism, low cancellation rates, and strong relationships with large pharma. Despite some uncertainties, such as the CEO transition and margin outlook, the company is focusing on cost-saving initiatives and operational improvements. The market cap suggests a moderate reaction, leading to a positive sentiment prediction of 2% to 8%.
FTRE Slides
FTRE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
